HotSpot Therapeutics

HotSpot Therapeutics

HotSpot Therapeutics was founded in Boston, Massachusetts, as a biotechnology company specializing in allosteric drug discovery, as per public records. The firm's SmartAllostery platform targets previously undruggable proteins by identifying regulatory hotspots, a structural insight that differentiates it from conventional drug discovery approaches. The company's strategy spans discovery through clinical development, with a focus on small-molecule therapeutics in immunology and oncology. HotSpot has disclosed collaborations and financing rounds, including a Series A and B funding from investors such as SR One and Google Ventures, per public announcements. The firm's pipeline includes programs for autoimmune diseases and solid tumors, though specific asset-stage details are not fully public. HotSpot's team includes scientific and operational professionals with experience in big pharma and biotech, but named executives and total headcount remain undisclosed. The company does not publicly report AUM or assets under management, as it operates as a research-driven drug developer rather than an investment manager. No recent operational event was confirmed within the last 24 months. HotSpot's differentiator is its SmartAllostery platform, which enables rational design of allosteric modulators — a structural capability that potentially reduces attrition rates in drug discovery. The firm's governance and fundraising structure suggests a model akin to a venture-backed biotech, though its long-term corporate architecture is not transparent.